New breakthrough has been made in the study of breast cancer targeted treatment

Dr. Xu Lingzhi and his research team from the Second Affiliated Hospital of Medical University in Dalian have made new achievements in the field of breast cancer stem cell properties and targeted therapy. The achievements describes the key regulating effect of p62 / SQSTM1-let-7a / b-MYC signaling pathway on breast cancer stem cell properties for the first time and indicates that signaling hub protein p62 / SQSTM1 can be an effective target for intervention, providing new thoughts for overcoming the recurrence, metastasis and drug resistance of breast cancer. Related research papers are recently published online in the journal Cancer Gene, which also publishes some other studies on recombinant human proteins.

Currently, the clinical treatment of breast cancer has been improved greatly, but the phenomenon of recurrence and drug resistance is becoming more serious. More and more evidence suggests that tumor stem cells are highly correlated with drug resistance, relapse and metastasis during tumor treatment. However, because of the dynamic evolution and high-degree heterogeneity of tumor stem cells, therapies aimed at cancer stem cells still lacks for effective targets and intervention mechanisms.

As a "signal hub" within the cell, p62 / SQSTM1 protein combines with a variety of signaling molecules through its own series of functional domains to be involved in the regulation of various signaling pathways. In the study, researchers took breast cancer as an example. By in-vitro and in-vivo animal experiments of cell lines, the researchers reveal the signaling protein p62 / SQSTM1 highly express in cancer stem cell enriched population for the first time, and it plays positive regulation role to "dry” character of tumor stem cells. Intervention of the expression of the gene can significantly reduce the "dry" character of tumor stem cells. The research team also found that the signaling protein p62 / SQSTM1 can promote mRNA stability after oncogene MYC transcription by reducing the expression of a small RNA-let-7a / b, thus mediating "dry" phenotype of tumor stem cells. Subsequent analysis of clinical samples further validated that the high expression of signaling protein p62 / SQSTM1 was negatively correlated with PFS and OS in breast cancer patients. Flarebio provides high-quality recombinant proteins such as recombinant CDH4 at good prices.